Minerva expects seltorexant findings to help define Phase 3 clinical program
The company said, "During 2019, the Company completed and announced top-line results from three Phase 2b trials and one Phase 1b trial with seltorexant. Three of these trials were in MDD and one was in insomnia disorder. Key conclusions following data analyses from these trials include the following. Seltorexant shows clinically meaningful and consistent improvements in mood and sleep symptoms. In depressed patients, seltorexant shows improvement in mood as monotherapy and as add-on therapy to SSRIs or SNRIs, and its effect on mood is stronger in patients with insomnia. Among the doses of seltorexant tested, 20 mg shows the most robust and consistent effect on mood. In both adult and elderly subjects, seltorexant improves both sleep induction and sleep maintenance compared to zolpidem. Seltorexant shows a safety and tolerability profile similar to placebo. These findings are expected to help define a Phase 3 clinical development program for seltorexant that potentially will encompass both MDD and insomnia."